According to a recent research report titled ” Formulation Development Outsourcing Market (By Service: Preformulation, Formulation Development; By Formulation: Topical, Oral, Injectable, Others; By Therapeutic Area: Oncology, Infectious Disease, Respiratory, Cardiovascular, Neurology, Hematology, Dermatology, Others; By End-User: Pharmaceutical Industries, Research and Academic Institutions) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032″ published by Precedence Research, the global formulation development outsourcing market size is projected to touch around USD 75.8 billion by 2032 and growing at a CAGR of 7.32% over the forecast period 2023 to 2032. This comprehensive study examines various factors and their impact on the growth of the formulation development outsourcing market.
Key Takeaways:
- By region, Asia- Pacific contributed more than 41% of revenue share in 2022, the region is anticipated to register the fastest growth rate during the forecast period.
- By service, the formulation development generated over 77% of revenue share in 2022.
- By formulation, the oral segment had the largest market share of 64% in 2022.
- By therapeutic area, the oncology segment carried the largest market share of 26% in 2022, the segment is expected to sustain its position during the forecast period.
- By end-user, the pharmaceutical industry segment is expected to be dominant in the market during the predicted period.
The report primarily focuses on the volume and value of the formulation development outsourcing market at the global, regional, and company levels. At the global level, the report analyzes historical data and future prospects to present an overview of the overall market size. Regionally, the study emphasizes key regions such as North America, Europe, the Middle East & Africa, Latin America, and others.
Furthermore, the research report provides specific segmentations based on regions (countries), companies, and all market segments. This analysis offers insights into the growth and revenue trends during the historical period of 2017 to 2032, as well as the projected period. By understanding these segments, it becomes possible to identify the significance of different factors that contribute to market growth.
Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3192
The research also highlights significant progressions in both organic and inorganic growth strategies within the global formulation development outsourcing market. Numerous companies are placing emphasis on new product launches, gaining product approvals, and implementing various business expansion tactics. Moreover, the report presents detailed profiles of firms operating in the formulation development outsourcing market, along with their respective market strategies. Additionally, the study concentrates on prominent industry participants, furnishing details such as company profiles, product offerings, financial updates, and noteworthy advancements.
Formulation Development Outsourcing Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 40.14 Billion |
| Market Size by 2032 | USD 75.8 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 7.32% |
| Largest Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 To 2032 |
| Segments Covered | By Service, By Formulation, By Therapeutic Area, and By End-User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Also read: Carbonated Beverage Market Size To Grow USD 654.37 Billion by 2032
Major Key Points Covered in Report:
Executive Summary: It includes key trends of the electric vehicle fuel cell market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the electric vehicle fuel cell market based on production and revenue.
Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.
Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Electric vehicle fuel cell market.
Market Segments: This part of the report discusses product, application and other segments of the electric vehicle fuel cell market based on market share, CAGR, market size, and various other factors.
Research Methodology: This section discusses the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.
Market Key Players
The report incorporates company profiles of key players in the market. These profiles encompass vital information such as product portfolio, key strategies, and a comprehensive SWOT analysis for each player. Additionally, the report presents a matrix illustrating the presence of each prominent player, enabling readers to gain actionable insights. This facilitates a thoughtful assessment of the market status and aids in predicting the level of competition in the formulation development outsourcing market.
Some of the prominent players in the formulation development outsourcing market include
- SGS S.A.
- Eurofins Scientific SE
- Element
- Labcorp
- Thermo Fisher Scientific, Inc. (Patheon)
- Intertek Group plc
- Recipharm
- Lonza
- Charles River Laboratories International, Inc.
- Catalent Inc.
Formulation Development Outsourcing Market Segmentations
By Service
- Preformulation
- Formulation Development
By Formulation
- Topical
- Oral
- Injectable
- Others
By Therapeutic Area
- Oncology
- Infectious Disease
- Respiratory
- Cardiovascular
- Neurology
- Hematology
- Dermatology
- Others
By End-User
- Pharmaceutical Industries
- Research and Academic Institutions
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Why should you invest in this report?
This report presents a compelling investment opportunity for those interested in the global formulation development outsourcing market. It serves as an extensive and informative guide, offering clear insights into this niche market. By delving into the report, you will gain a comprehensive understanding of the various major application areas for formulation development outsourcing. Furthermore, it provides crucial information about the key regions worldwide that are expected to experience substantial growth within the forecast period of 2023-2030. Armed with this knowledge, you can strategically plan your market entry approaches.
Moreover, this report offers a deep analysis of the competitive landscape, equipping you with valuable insights into the level of competition prevalent in this highly competitive market. If you are already an established player, it will enable you to assess the strategies employed by your competitors, allowing you to stay ahead as market leaders. For newcomers entering this market, the extensive data provided in this report is invaluable, providing a solid foundation for informed decision-making.
Some of the key questions answered in this report:
- What is the size of the overall Formulation development outsourcing market and its segments?
- What are the key segments and sub-segments in the market?
- What are the key drivers, restraints, opportunities and challenges of the Formulation development outsourcing market and how they are expected to impact the market?
- What are the attractive investment opportunities within the Formulation development outsourcing market?
- What is the Formulation development outsourcing market size at the regional and country-level?
- Who are the key market players and their key competitors?
- What are the strategies for growth adopted by the key players in Formulation development outsourcing market?
- What are the recent trends in Formulation development outsourcing market? (M&A, partnerships, new product developments, expansions)?
- What are the challenges to the Formulation development outsourcing market growth?
- What are the key market trends impacting the growth of Formulation development outsourcing market?
Table of Content:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Formulation Development Outsourcing Market
5.1. COVID-19 Landscape: Formulation Development Outsourcing Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Formulation Development Outsourcing Market, By Service
8.1. Formulation Development Outsourcing Market, by Service, 2023-2032
8.1.1. Preformulation
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Formulation Development
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Formulation Development Outsourcing Market, By Formulation
9.1. Formulation Development Outsourcing Market, by Formulation, 2023-2032
9.1.1. Topical
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Oral
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Injectable
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Formulation Development Outsourcing Market, By Therapeutic Area
10.1. Formulation Development Outsourcing Market, by Therapeutic Area, 2023-2032
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Infectious Disease
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Respiratory
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Cardiovascular
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Neurology
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Hematology
10.1.6.1. Market Revenue and Forecast (2020-2032)
10.1.7. Dermatology
10.1.7.1. Market Revenue and Forecast (2020-2032)
10.1.8. Others
10.1.8.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Formulation Development Outsourcing Market, By End-User
11.1. Formulation Development Outsourcing Market, by End-User, 2023-2032
11.1.1. Pharmaceutical Industries
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Research and Academic Institutions
11.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Formulation Development Outsourcing Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.1.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.4. Market Revenue and Forecast, by End-User (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End-User (2020-2032)
Chapter 13. Company Profiles
13.1. SGS S.A.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eurofins Scientific SE
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Element
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Labcorp
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Thermo Fisher Scientific, Inc. (Patheon)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Intertek Group plc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Recipharm
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Lonza
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Charles River Laboratories International, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Catalent Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
